Just simply getting old, from age 50 to 75, increased risk for Alzheimer’s disease by 100-fold, which really dwarfed 10-fold ...

The U.S. Department of Justice recently announced the formation of a task force that will advocate the roll-back of regulations that affect a wide swath of sectors of the American economy. Health care ...

First quarter earnings reports from Edwards Lifesciences Corp., Intuitive Surgical Inc. and Boston Scientific Corp. support trends seen earlier: Larger med-tech companies expect substantial tariff ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

A large-scale study has revealed the impact of germline variants on proteins in 10 cancer types. Scientists from the National ...

Rona Therapeutics Co. Ltd. has obtained IND clearance from China′s National Medical Products Administration (NMPA) for RN-1871, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) for ...

It’s time for the U.S. Congress to finally put some guardrails on the 340B prescription drug discount program it created more than 30 years ago as a way to help fund health care for low-income ...

Gastrointestinal stromal tumors (GISTs) are a diverse group of tumors that account for about 80% of mesenchymal neoplasms in the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) against KIT ...

Avidicure BV has launched with a $50 million seed financing round and a focus on developing dual agonistic, multifunctional and avidity engineered antibodies, or AVC-Boosters, to deliver targeted and ...

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders ...

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has been granted IND clearance by the FDA for its antibody-drug conjugate (ADC) drug SKB-518.

Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural ...